LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・MacroGenics Inc

MacroGenics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.71

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.71

Max

1.71

Pagrindiniai rodikliai
By Trading Economics
Pajamos	53M 17M
Pardavimai	51M 73M
Pelno marža	23.095
Darbuotojai	341
EBITDA	55M 22M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+132.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	23M 114M
Ankstesnė atidarymo kaina	1.71
Ankstesnė uždarymo kaina	1.71

Naujienos nuotaikos

By Acuity

50%

155 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

1.47 / 1.64 Palaikymas ir pasipriešinimas

MacroGenics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-13 16:32; UTC

Uždarbis

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026-02-13 21:57; UTC

Uždarbis

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026-02-13 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:20; UTC

Uždarbis

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026-02-13 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026-02-13 20:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-13 20:45; UTC

Rinkos pokalbiai

Dollar Pares Down Early Losses -- Market Talk

2026-02-13 20:39; UTC

Rinkos pokalbiai

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026-02-13 20:28; UTC

Rinkos pokalbiai

Oil Settles Week Lower -- Market Talk

2026-02-13 19:51; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:29; UTC

Uždarbis

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026-02-13 18:18; UTC

Įsigijimai, susijungimai, perėmimai

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026-02-13 17:52; UTC

Uždarbis

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026-02-13 17:16; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026-02-13 16:59; UTC

Uždarbis

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026-02-13 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026-02-13 16:11; UTC

Uždarbis

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026-02-13 16:07; UTC

Rinkos pokalbiai

Hungarian Forint Could Rise Further -- Market Talk

2026-02-13 15:54; UTC

Uždarbis

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026-02-13 15:26; UTC

Rinkos pokalbiai

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026-02-13 15:01; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026-02-13 15:00; UTC

Uždarbis

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026-02-13 14:50; UTC

Rinkos pokalbiai

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026-02-13 14:44; UTC

Uždarbis

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026-02-13 14:22; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-13 14:21; UTC

Rinkos pokalbiai

Uždarbis

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026-02-13 14:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Move Lower -- Market Talk

Akcijų palyginimas

Kainos pokytis

MacroGenics Inc Prognozė

Kainos tikslas

By TipRanks

132.56% į viršų

12 mėnesių prognozė

Vidutinis 4 USD 132.56%

Aukščiausias 4 USD

Žemiausias 4 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MacroGenics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių MacroGenics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.47 / 1.64Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

155 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.